RCSI research has found that Venetoclax, a medication currently approved for leukemia, has benefits for patients with multiple myeloma when used in combination with another drug. This discovery offers a new avenue of treatment options for the currently incurable disease.

Multiple myeloma (MM) is a type of blood cancer that is newly diagnosed in around 400 people in Ireland each year. Despite treatment advances in recent years, it remains incurable.

The search for innovative treatment strategies is crucial, particularly for patients whose cancer is resistant to standard care. In the new study published in Haematologica, researchers at the RCSI Department of Physiology and Medical Physics and the Beaumont RCSI Cancer Centre set out to identify complementary drugs that would enhance the efficiency of Venetoclax, a drug approved for use in leukemia, for MM treatment.

Know more: https://www.sciencedaily.com/releases/2024/03/240325135716.htm

• Tags:
• News